Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice

Gene Therapy

Volumn 14, Issue 1, 2007, Pages 20-29

  Hung, C F ^a,e   Tsai, Y C ^a   He, L ^a   Coukos, G ^b,c   Fodor, I ^d   Qin, L ^a   Levitsky, H ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Center for Research on Reproduction and Women's Health   (United States)

^d LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antitumor effects; Luciferase; Ovarian cancer; Vaccinia virus

Indexed keywords

NATURAL PRODUCT; VACCINIA VIRUS EXTRACT;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LUMINESCENCE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; HUMANS; LUCIFERASES; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; TRANSFECTION; VACCINIA; VACCINIA VIRUS;

MURINAE; MUS; VACCINIA VIRUS;

EID: 33845665403     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302840     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women [see comments]. Lancet 1992; 339: 1-15.
2. Baum M, Ebb S, Brooks M. Biological fall out from trials of adjuvant tamoxifen in early ovarian cancer. In: Salmon SE (ed). Adjuvant Therapy of Cancer V1. WB Saunders: Philadelphia, 1990, pp 269-274.
3. Swain SM. Selection of therapy for stage III breast cancer. Surg Clin N Am 1990; 70: 1061-1080.
4. Peng KW, TenEyck CJ, Galanis E, Kalh KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
5. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: Teaching new tricks to an old dog. Mol Ther 2005; 11: 180-195.
6. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004; 22: 70-77.
7. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast Jr RC et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003; 9: 2727-2733.
8. Hu Y, Lee J, McCart JA, Xu H, Moss B, Alexander HR et al. Yabalike disease virus: An alternative replicating poxvirus vector for cancer gene therapy. J Virol 2001; 75: 10300-10308.
9. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR et al. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66-73.
10. Gnant MF, Puhlmann M, Alexander Jr HR, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999; 59: 3396-3403.
11. Gnant MF, Puhlmann M, Bartlett DL, Alexander Jr HR. Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann Surg 1999; 230: 352-360 (discussion 360-351).
12. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757.
13. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
14. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R et al. Phase I study of sequential vaccinations with fowlpoxCEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with cardnoembryonic antigen-expressing carcinomas. J Clin Oncol 2005; 23: 720-731.
15. Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004; 23: 106-110.
16. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5: 690-699.
17. Mastrangelo MJ, Maguire Jr HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422.
18. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HJ, Mulholland SG, Lattime EC. Phase i study of intravesicle vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001; 166: 1291-1295.
19. Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol 2005; 17: 456-461.
20. Thorne SH, Hwang TH, Kirn DH. Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther 2005; 7: 359-365.
21. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. Biolumimescence imaging of vaccinia virus: Effects of interferon on viral replication and spread. Virology 2005; 341: 284-300.
22. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-320.
23. Gnant MF, Noll LA, Irvine KR, Puhlmann M, Terrill RE, Alexander Jr HR et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst 1999; 91: 1744-1750.
24. Karupiah G, Coupar B, Ramshaw I, Boyle D, Blanden R, Andrew M. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol Cell Biol 1990; 68 (Part 5): 325-333.
25. Sedger L, Ruby J. Heat shock response to vaccinia virus infection. J Virol 1994; 68: 4685-4689.
26. Chen B, Timiryasova TM, Haghighat P, Andres ML, Kajioka EH, Dutta-Roy R et al. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 2001; 24: 46-57.
27. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L et al. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci 1995; 92: 11671-11675.
28. Chisholm SE, Reyburn HT. Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol 2006; 80: 2225-2233.
29. Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS et al. Antitumor effect of vaccinia virus in glioma model. Oncol Res 1999; 11: 133-144.
30. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005; 173: 604-609.
31. Conejo-Garda JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950-958.